Review Papers Claim by Claim

• Known from experiments: Rtt109 is required for detectable H3-K56 acetylation in yeast deletion/mutant backgrounds; recombinant/yeast-purified Rtt109 acetylates H3-K56 in vitro. Experimental evidence for Rtt109→H3K56 acetylation
• Inference (but biologically plausible): the observed genotoxic sensitivity and elevated Rad52 foci are mainly mediated by the loss of H3-K56 acetylation (supported by epistasis-style reasoning using H3-K56 mutants and catalytic rtt109 mutants). Genotoxic sensitivity and Rad52 foci tied to H3K56
• Uncertain / not fully resolved by this paper alone: whether Rtt109 has additional essential substrates or co-chaperone dependencies beyond what is tested here (e.g., broad substrate scope, cell-type generality, and replication-stage mechanistic placement). Scope/limits of substrate mapping in this study

• The authors screened 4700 viable yeast deletion mutants using an antibody specific for H3-K56Ac, identifying ASF1 and RTT109 as deletions that abolish detectable H3-K56 acetylation. 4700-mutant screen identifies ASF1/RTT109
• They validated specificity by showing H3K79 methylation was unaffected in the relevant mutants. Mark specificity control: H3K79me unaffected

• Purified recombinant Rtt109 incorporates acetyl label from [3H]acetyl-CoA when incubated with H3/H4 tetramers, showing concentration-dependent acetyl incorporation. In vitro [3H]acetyl-CoA incorporation by Rtt109
• Rtt109 acetylates itself and H3-K56 (but not H4) in vitro, and Rtt109 purified from yeast cells also acetylates H3-K56. Rtt109 acetylates H3-K56 in vitro

• The authors argue Rtt109 lacks homology to canonical HAT families and identify conserved aspartate (D) residues needed for activity by creating multiple D/E→A mutants. Two variants (including D89A and DD287-288AA) abolish H3-K56 acetylation in vivo, and D89N similarly abolishes while DD287-288NN reduces. Aspartate catalytic residues control H3K56Ac
• They further test in vitro activity of yeast-purified mutant Rtt109 proteins, showing selected aspartate mutants lose the ability to acetylate H3. They also show mutant Rtt109 proteins still bind Vps75, arguing against wholesale misfolding as the explanation. Catalytic loss without Vps75 binding loss

• Yeast lacking Rtt109 or expressing rtt109 mutants that abolish H3-K56 acetylation show increased sensitivity to genotoxic agents including camptothecin, hydroxyurea, and MMS, with sensitivity matching that of H3-K56 mutants. Genotoxin sensitivity correlates with H3K56Ac loss
• They quantify spontaneous Rad52-YFP foci (repair/lesion signaling foci) and observe increased Rad52 foci in rtt109Δ and H3-K56 mutant cells, with the effect mainly attributable to loss of H3-K56 acetylation. Rad52 foci increase reflects H3K56Ac loss
• Finally, they present genetic interactions between rtt109D and replication/repair genes (PCNA pol30 alleles, DNA polymerase α, and other replication-associated mutants), supporting a functional link between H3-K56 acetylation and DNA replication processes. Genetic interactions place Rtt109 into replication stress network

4) Skeptical critique & blind spots

• Antibody readout bias: The primary discovery of abolished H3-K56 acetylation relies on antibody detection (H3-K56Ac). If antibody specificity/epitope accessibility differs among mutants, false “loss” could occur. The paper mitigates this with additional controls (e.g., unchanged H3K79me), but comprehensive orthogonal quantification (e.g., site-specific mass spectrometry for all mutants) is not shown in the excerpted main text. H3K56Ac antibody reliance; specificity partially controlled
• In vitro reconstitution ≠ full cellular regulation: Recombinant Rtt109 acetylates H3-K56 in vitro, but the in vivo context includes chromatin state, replication timing, and cofactors that can modulate substrate access. The authors partially address this with genetics and catalytic mutants, yet the exact replication-stage placement mechanism is not mechanistically dissected beyond genetic linkage. Mechanistic placement remains partly indirect in this study
• Specificity scope: They state acetylation specificity for H3-K56 over H4, and also report that other H3 lysines (e.g., K9, K14, K18, K23) are not altered in rtt109Δ cells (asynchronous). However, “global H3 PTM landscape” specificity across all conditions/stages is not exhaustively mapped in the provided main text. Measured specificity: H4 not acetylated; some other H3 lysines unchanged
• Species generalization: The study is in budding yeast; while the biochemistry may generalize, the replication stress circuitry and compensation can differ across eukaryotes. The paper itself frames the discovery in yeast. Yeast-centered experimental model

5) What would most strongly disprove the paper’s core claim?

• Demonstrating that H3-K56 acetylation occurs in yeast cells even when Rtt109 is absent and catalytic-site mutants are introduced (i.e., no H3-K56Ac loss at the level of independent quantification). Necessity of Rtt109 for H3K56Ac asserted by the paper
• Showing that catalytic mutants that retain H3-K56 acetylation fail to show genotoxic sensitivity (i.e., decoupling between H3-K56 acetylation and the observed DNA damage phenotypes). Phenotype-to-mark coupling claimed in the paper
• In vitro/biochemical: showing recombinant Rtt109 cannot acetylate H3-K56 under the same assay conditions (or that observed acetyl label targets a different lysine/site). Biochemical requirement for site-specific H3K56 acetylation

6) Evidence type distribution (qualitative, from the paper’s design)